2,514 results on '"Go, Ronald"'
Search Results
2. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events
3. Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms
4. Clinical features and outcomes in primary nervous system histiocytic neoplasms
5. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
6. Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
7. Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
8. Venous and arterial thrombosis in patients with VEXAS syndrome
9. A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura
10. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
11. Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
12. Neurological Manifestations of Histiocytic Disorders
13. Analysis of Medicare Expenditure for Discarded Infused Cancer Therapeutics From 2017-2020
14. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
15. Long-term outcomes among adults with Langerhans cell histiocytosis
16. Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells
17. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
18. Spectrum of clonal hematopoiesis in VEXAS syndrome
19. Pulmonary manifestations in VEXAS syndrome
20. Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis
21. Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes
22. Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)
23. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
24. Race, rituximab, and relapse in TTP
25. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
26. SLC29A3 Pathogenic Variants Resulting in Dural Based Fibroinflammatory Mass Lesions and H Syndrome Treated With Cobimetinib: A Case Report.
27. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
28. Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis
29. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval
30. Erythrocytosis in Patients on Testosterone Therapy
31. Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
32. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
33. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center
34. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update
35. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy
36. Prognostic restaging after treatment initiation in patients with AL amyloidosis
37. Coagulation Abnormalities in Light Chain Amyloidosis
38. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
39. Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations
40. Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations.
41. A comprehensive review on gelatinous transformation of the bone marrow.
42. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
43. Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis
44. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients
45. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
46. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
47. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma
48. Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer
49. Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic
50. C3+ and C3− warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.